5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.18▲ | 2.16▲ | 2.17▲ | 2.39▼ | 2.39▼ |
MA10 | 2.16▲ | 2.18▲ | 2.25▼ | 2.38▼ | 2.45▼ |
MA20 | 2.15▲ | 2.27▼ | 2.34▼ | 2.43▼ | 2.21▼ |
MA50 | 2.16▲ | 2.37▼ | 2.41▼ | 2.49▼ | 3.81▼ |
MA100 | 2.25▼ | 2.41▼ | 2.43▼ | 2.18▲ | 4.19▼ |
MA200 | 2.34▼ | 2.44▼ | 2.46▼ | 3.28▼ | 4.93▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.007▲ | -0.005▼ | -0.023▼ | -0.019▼ | 0.109▲ |
RSI | 62.523▲ | 34.748▼ | 32.684▼ | 40.627▼ | 41.833▼ |
STOCH | 85.714▲ | 18.196▼ | 9.785▼ | 32.826 | 41.931 |
WILL %R | 0.000▲ | -75.862▼ | -84.091▼ | -85.246▼ | -73.016 |
CCI | 96.120 | -40.941 | -78.763 | -216.755▼ | -70.223 |
Monday, August 18, 2025 01:19 PM
Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory ...
|
Thursday, August 14, 2025 01:17 PM
Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability ...
|
Thursday, August 14, 2025 09:22 AM
Annexon reported a GAAP net loss per share of $0.34 for Q2 2025, narrower than the consensus GAAP estimate of $ (0.37). Research and development expenses climbed 76.8% year over year (GAAP).
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
19/08/25 | 2.35 | 2.35 | 2.10 | 2.19 | 1,993,918 |
18/08/25 | 2.47 | 2.567 | 2.34 | 2.35 | 1,893,967 |
15/08/25 | 2.45 | 2.575 | 2.35 | 2.44 | 2,662,783 |
14/08/25 | 2.55 | 2.60 | 2.34 | 2.38 | 1,323,176 |
13/08/25 | 2.47 | 2.71 | 2.45 | 2.60 | 1,910,799 |
12/08/25 | 2.38 | 2.45 | 2.35 | 2.44 | 417,715 |
11/08/25 | 2.36 | 2.40 | 2.31 | 2.35 | 466,278 |
08/08/25 | 2.39 | 2.4342 | 2.335 | 2.36 | 1,103,298 |
07/08/25 | 2.35 | 2.39 | 2.305 | 2.37 | 884,551 |
06/08/25 | 2.44 | 2.45 | 2.35 | 2.35 | 569,428 |
|
|
||||
|
|
||||
|
|